文献速递生殖医学产科

冷冻与新鲜供卵的围产期良好结局发生率比较

Prevalence of a Good Perinatal Outcome With Cryopreserved Compared With Fresh Donor Oocytes.
PubMed 文献 · Obstet Gynecol · 2020-01-01

基于美国辅助生殖技术临床结局报告系统2012–2015年数据,回顾性分析36,925个供卵IVF周期,冷冻卵母细胞组围产期良好结局(足月单胎活产且出生体重2,500–4,000g)为22.0%,新鲜组为24.1%,校正后OR 0.88(95%CI 0.81–0.95)。冷冻组活产率、多胎率和早产率均较低。

要点

  • 冷冻供卵周期的围产期良好结局几率略低于新鲜供卵(22.0% vs 24.1%,校正OR 0.88)。
  • 冷冻供卵与较低活产率(39.6% vs 47.7%)、多胎率(22.3% vs 31.2%)和早产率(27.6% vs 30.6%)相关。
  • 该研究为回顾性队列,不能排除残余混杂,临床决策需结合个体情况。

核心结论

  • 在供卵IVF周期中,使用冷冻卵母细胞相比新鲜卵母细胞与围产期良好结局几率略低相关。

研究设计与样本

  • 回顾性队列研究,利用美国辅助生殖技术临床结局报告系统(SART CORS)2012–2015年数据。
  • 共纳入36,925个供卵IVF周期,其中冷冻卵母细胞8,381个(22.7%),新鲜卵母细胞28,544个(77.3%)。
  • 排除使用冷冻胚胎、妊娠代孕或植入前遗传学检测的周期。
  • 采用广义估计方程模型校正协变量和同一患者重复周期的相关性。

主要发现

  • 围产期良好结局(足月单胎活产且出生体重2,500–4,000g)发生率冷冻组22.0%,新鲜组24.1%,未校正OR 0.90(95%CI 0.85–0.96),校正OR 0.88(95%CI 0.81–0.95)。
  • 活产率冷冻组39.6%,新鲜组47.7%,OR 0.75(95%CI 0.72–0.79)。
  • 多胎率冷冻组22.3%,新鲜组31.2%,OR 0.63(95%CI 0.58–0.69)。
  • 早产率冷冻组27.6%,新鲜组30.6%,OR 0.86(95%CI 0.79–0.94)。

临床怎么用

  • 咨询供卵IVF患者时,可告知冷冻供卵的围产期良好结局几率略低于新鲜供卵,但多胎和早产风险也较低。
  • 选择卵母细胞类型需综合评估活产率、多胎风险及围产期结局,个体化决策。

局限性

  • 回顾性研究设计,可能存在未测量混杂因素。
  • 仅纳入2012–2015年数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the odds of a good perinatal outcome between cryopreserved and fresh donor oocytes. METHODS: We used the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System to conduct a retrospective cohort study of women undergoing donor oocyte in vitro fertilization (IVF) from 2012 to 2015. Cycles using cryopreserved embryos, a gestational carrier, or preimplantation genetic testing were excluded. The primary outcome was a good perinatal outcome, defined as a singleton live birth at 37 weeks of gestation or more with birth weight at or within 2,500 g and 4,000 g. Secondary outcomes included live birth, multiple birth, and prematurity. Generalized estimating equation models were used to test the effect of oocyte type on the primary outcome while accounting for covariates and the correlation induced by repeated cycles within a patient. RESULTS: Of the 36,925 cycles included in the analysis, 8,381 (22.7%) used cryopreserved and 28,544 (77.3%) used fresh oocytes. The odds of a good perinatal outcome were marginally but significantly lower with cryopreserved than with fresh oocytes before and after covariate adjustment (22.0% vs 24.1%, unadjusted odds ratio [OR] 0.90, 95% CI 0.85-0.96, adjusted OR 0.88, 95% CI 0.81-0.95). Compared with fresh oocytes, cryopreserved oocytes were associated with lower rates of live birth (39.6% vs 47.7%, OR 0.75, 95% CI 0.72-0.79), multiple birth (22.3% vs 31.2%, OR 0.63, 95% CI 0.58-0.69), and prematurity (27.6% vs 30.6%, OR 0.86, 95% CI 0.79-0.94). CONCLUSION: This retrospective national study demonstrated that the use of cryopreserved compared with fresh donor oocytes in IVF cycles is associated with marginally lower odds of a good perinatal outcome.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Eaton JL, Truong T, Li YJ, et al. Prevalence of a Good Perinatal Outcome With Cryopreserved Compared With Fresh Donor Oocytes. Obstet Gynecol. 2020. PMID: 32028490. doi:10.1097/AOG.0000000000003695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。